LWM
MRNA icon

Laidlaw Wealth Management’s Moderna MRNA Stock Holding History

Laidlaw Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,533
Closed -$235K – 366
2023
Q1 		$235K Hold
1,533
– – 0.05% 304
2022
Q4 		$275K Sell
1,533
-310
-17% -$50.7K 0.06% 279
2022
Q3 		$218K Buy
1,843
+200
+12% +$30.3K 0.05% 287
2022
Q2 		$235K Sell
1,643
-122
-7% -$17.4K 0.05% 314
2022
Q1 		$304K Sell
1,765
-1,050
-37% -$177K 0.05% 298
2021
Q4 		$715K Buy
2,815
+551
+24% +$161K 0.11% 180
2021
Q3 		$871K Buy
2,264
+113
+5% +$41.7K 0.22% 102
2021
Q2 		$505K Sell
2,151
-520
-19% -$92.9K 0.13% 149
2021
Q1 		$350K Buy
2,671
+246
+10% +$35.6K 0.12% 152
2020
Q4 		$253K Buy
+2,425
New +$245K 0.05% 296

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Laidlaw Wealth Management's MRNA Position: Q2 2023 in Review

Laidlaw Wealth Management sold out of Moderna (MRNA) in Q2 2023, closing a stake of 1,533 shares — an estimated $235K sold.

Laidlaw Wealth Management first reported a position in MRNA in Q4 2020 and held it in 10 quarters. The position peaked at $871K in Q3 2021. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Laidlaw Wealth Management reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Laidlaw Wealth Management sold 1,533 Moderna shares in Q2 2023, an estimated $235K.
  • Laidlaw Wealth Management first reported a position in Moderna in Q4 2020 and held it in 10 quarters.
  • Laidlaw Wealth Management's Moderna position peaked at $871K in Q3 2021.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Laidlaw Wealth Management's 13F filing for Q2 2023, filed 14 Aug 2023.